Article

CHF2819: pharmacological profile of a novel acetylcholinesterase inhibitor.

Department of Pharmacology and Human Physiology, Medical School, University of Bari, Policlinico, Piazza Giulio Cesare 11, 70124 Bari, Italy. .
CNS Drug Reviews (Impact Factor: 4.92). 02/2002; 8(1):53-69. DOI: 10.1111/j.1527-3458.2002.tb00215.x
Source: PubMed

ABSTRACT CHF2819 is a novel orally active acetylcholinesterase inhibitor (AChEI) developed for the treatment of Alzheimer's disease (AD). CHF2819 is a selective inhibitor of AChE, it is 115 times more potent against this enzyme than against butyrylcholinesterase (BuChE). Moreover, CHF2819 is more selective for inhibition of central (brain) AChE than peripheral (heart) AChE. In vivo CHF2819, 0.5, 1.5, and 4.5 mg/kg p.o., significantly and in dose-dependent manner increased acetylcholine (ACh) levels in hippocampus of young adult rats. Moreover, aging animals, with lower basal ACh levels than young adult rats, also exhibit a marked increase in hippocampal levels of this neurotransmitter after administration of CHF2819. At 1.5 mg/kg p.o. CHF2819 attenuated scopolamine-induced amnesia in a passive avoidance task. Furthermore, it decreased dopamine (DA) levels and increased extracellular levels of 5-hydroxytryptamine (5-HT) in the hippocampus, without modifying norepinephrine (NE) levels. By oral administration to young adult rats CHF2819 did not affect extracellular hippocampal levels of glutamate (Glu), aspartate (Asp), gamma-aminobutyric acid (GABA), taurine (Tau), arginine (Arg) or citrulline (Cit). Functional observational battery (FOB) screening demonstrated that CHF2819 (1.5 and 4.5 mg/kg p.o.) does not affect activity, excitability, autonomic, neuromuscular, and sensorimotor domains, as well as physiological endpoints (body weight and temperature). CHF2819 induced, however, involuntary motor movements (ranging from mild tremors to myoclonic jerks) in a dose-dependent manner. The neurochemical and behavioral profiles of CHF2819 suggest that this orally active novel AChEI could be of clinical interest for the treatment of Alzheimer-type dementia associated with multiple neurotransmitter abnormalities in the brain. In particular, CHF2819 might be a useful therapeutic drug for AD patients with cognitive impairment accompanied by depression.

0 Bookmarks
 · 
76 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: (-)-(3aS,8aS,1S)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol-2′-ethylphenylcarbamate N-oxide hydrochloride (CHF2819) is a novel, orally active acetylcholinesterase inhibitor (AChEI) for Alzheimer's disease (AD). CHF2819 appears as a selective inhibitor of AChE, being 115 times more potent against this enzyme than butyrylcholinesterase (BuChE). Moreover, CHF2819 appears more selective for inhibiting central (brain) than peripheral (heart) AChE. In vivo studies show that CHF2819 significantly increases acetylcholine (ACh) levels in young adult rat hippocampus in a dose-dependent manner. Moreover, aged animals exhibit a marked increase in hippocampal concentrations of this neurotransmitter after the administration of CHF2819. This compound attenuates scopolamine-induced amnesia in a passive avoidance task. Furthermore, CHF2819 induces a significant decrease in dopamine (DA) levels and a significant elevation of hippocampal extracellular concentrations of 5-hydroxytryptamine (5-HT), while it does not modify noradrenaline (NA) levels. Oral administration of CHF2819 does not affect hippocampal extracellular glutamate (Glu), aspartate (Asp), -aminobutyric acid (GABA), taurine (Tau), arginine (Arg), and citrulline (Cit) concentrations of young adult rats. Functional observational battery (FOB) screening demonstrates that CHF2819 (1.5 and 4.5 mg/kg p.o.) does not affect activity, excitability, autonomic, neuromuscular, and sensorimotor domains, as well as physiological endpoints. However, this compound induces involuntary motor movements in a dose-dependent manner. In conclusion, the neurochemical and behavioral profile of CHF2819 suggests that this orally active novel AChEI could be of clinical interest for the treatment of Alzheimer-type dementia associated with multiple neurotransmitter abnormalities in the brain. In particular, CHF2819 might be a useful therapeutic drug for AD patients in which the cognitive impairment is accompanied by a depressive syndrome. Drug Dev. Res. 56:354–368, 2002. © 2002 Wiley-Liss, Inc.
    Drug Development Research 06/2002; 56(3):354 - 368. · 0.87 Impact Factor
  • Source
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP. 07/2012; 22(7):476-7.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This review presents a concise update on the inhibitors of the neuroenzyme, Acetylcholinesterase (AChE; EC 3.1.1.7). AChE is a serine protease, which hydrolyses Acetylcholine neurotransmitter into Acetate & Choline & hence, terminates neurotransmission. Molecular interactions (mode of binding to the target enzyme), clinical applications and limitations have been summarized for each of the inhibitors discussed. Traditional inhibitors (e.g. Physostigmine, Tacrine, Donepezil, Rivastigmine etc.) as well as novel inhibitors like various Physostigmine-derivatives have been covered. This is followed by a short glimpse on inhibitors derived from nature (e.g. Huperzine A & B, Galangin). Also, a discussion on 'hybrids of pre existing drugs' has been incorporated. Furthermore, current status of therapeutic applications of AChE-inhibitors has also been summarized.
    CNS & neurological disorders drug targets 01/2014; 13(3):391-401. · 3.57 Impact Factor

Full-text (2 Sources)

Download
0 Downloads
Available from
Jan 19, 2015

luigia trabace